tiprankstipranks
Celldex Therapeutics (CH:TCE1)
NASDAQ:TCE1
Switzerland Market
TCE1
Celldex
RESEARCH TOOLSreports

Celldex (TCE1) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

TCE1 Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Celldex
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TCE1 Stock 12 Month Forecast

Average Price Target

$41.09
Based on 11 Wall Street analysts offering 12 month price targets for Celldex in the last 3 months. The average price target is $41.09 with a high forecast of $53.88 and a low forecast of $30.56. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$53.88Average Price Target$41.09Lowest Price Target$30.56
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on CH:TCE1
Derek Archila
Wells Fargo
Wells Fargo
CHF43.43
Buy
―
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Celldex (NASDAQ: CLDX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
UBS Analyst forecast on CH:TCE1
David Dai
UBS
UBS
CHF36.19
Buy
―
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
LifeSci Capital Analyst forecast on CH:TCE1
Sam Slutsky
LifeSci Capital
LifeSci Capital
CHF53.88
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
H.C. Wainwright Analyst forecast on CH:TCE1
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF33.78
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Celldex (NASDAQ: CLDX) and Mirum Pharmaceuticals (NASDAQ: MIRM)
Cantor Fitzgerald Analyst forecast on CH:TCE1
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF53.88
Buy
―
Reiterated
06/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on CH:TCE1
Andy Chen
Wolfe Research
Wolfe Research
CHF41.01→CHF35.38
Buy
―
Reiterated
06/14/26
Celldex (CLDX) Receives a Buy from Wolfe Research
Morgan Stanley Analyst forecast on CH:TCE1
Judah Frommer
Morgan Stanley
Morgan Stanley
CHF35.38
Buy
―
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Evolent Health (NYSE: EVH) and Celldex (NASDAQ: CLDX)
Barclays Analyst forecast on CH:TCE1
Etzer Darout
Barclays
Barclays
CHF36.19→CHF38.6
Buy
―
Assigned
05/08/26
Celldex (CLDX) Receives a Buy from Barclays
Canaccord Genuity Analyst forecast on CH:TCE1
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF49.86
Buy
―
Reiterated
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Owlet (OWLT)
Goldman Sachs Analyst forecast on CH:TCE1
Richard Law CFA
Goldman Sachs
Goldman Sachs
CHF27.34→CHF30.56
Hold
―
Reiterated
05/08/26
Celldex price target raised to $38 from $34 at Goldman SachsCelldex price target raised to $38 from $34 at Goldman Sachs
TD Cowen Analyst forecast on CH:TCE1
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
Stifel Nicolaus Analyst forecast on CH:TCE1
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
CHF46.64→CHF54.68
Buy
―
Reiterated
02/26/26
Celldex price target raised to $68 from $58 at StifelCelldex price target raised to $68 from $58 at Stifel
Guggenheim Analyst forecast on CH:TCE1
Yatin Suneja
Guggenheim
Guggenheim
CHF72.38
Buy
―
Reiterated
02/26/26
Guggenheim Sticks to Their Buy Rating for Celldex (CLDX)
Mizuho Securities Analyst forecast on CH:TCE1
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
CHF38.6
Buy
―
Reiterated
01/09/26
Celldex (CLDX) Gets a Buy from Mizuho Securities
Citi Analyst forecast on CH:TCE1
David Lebowitz
Citi
Citi
CHF45.03→CHF38.6
Buy
―
Reiterated
08/20/25
Celldex price target lowered to $48 from $56 at CitiCelldex price target lowered to $48 from $56 at Citi
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on CH:TCE1
Derek Archila
Wells Fargo
Wells Fargo
CHF43.43
Buy
―
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Celldex (NASDAQ: CLDX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
UBS Analyst forecast on CH:TCE1
David Dai
UBS
UBS
CHF36.19
Buy
―
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
LifeSci Capital Analyst forecast on CH:TCE1
Sam Slutsky
LifeSci Capital
LifeSci Capital
CHF53.88
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
H.C. Wainwright Analyst forecast on CH:TCE1
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF33.78
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Celldex (NASDAQ: CLDX) and Mirum Pharmaceuticals (NASDAQ: MIRM)
Cantor Fitzgerald Analyst forecast on CH:TCE1
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF53.88
Buy
―
Reiterated
06/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on CH:TCE1
Andy Chen
Wolfe Research
Wolfe Research
CHF41.01→CHF35.38
Buy
―
Reiterated
06/14/26
Celldex (CLDX) Receives a Buy from Wolfe Research
Morgan Stanley Analyst forecast on CH:TCE1
Judah Frommer
Morgan Stanley
Morgan Stanley
CHF35.38
Buy
―
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Evolent Health (NYSE: EVH) and Celldex (NASDAQ: CLDX)
Barclays Analyst forecast on CH:TCE1
Etzer Darout
Barclays
Barclays
CHF36.19→CHF38.6
Buy
―
Assigned
05/08/26
Celldex (CLDX) Receives a Buy from Barclays
Canaccord Genuity Analyst forecast on CH:TCE1
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF49.86
Buy
―
Reiterated
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Owlet (OWLT)
Goldman Sachs Analyst forecast on CH:TCE1
Richard Law CFA
Goldman Sachs
Goldman Sachs
CHF27.34→CHF30.56
Hold
―
Reiterated
05/08/26
Celldex price target raised to $38 from $34 at Goldman SachsCelldex price target raised to $38 from $34 at Goldman Sachs
TD Cowen Analyst forecast on CH:TCE1
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
Stifel Nicolaus Analyst forecast on CH:TCE1
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
CHF46.64→CHF54.68
Buy
―
Reiterated
02/26/26
Celldex price target raised to $68 from $58 at StifelCelldex price target raised to $68 from $58 at Stifel
Guggenheim Analyst forecast on CH:TCE1
Yatin Suneja
Guggenheim
Guggenheim
CHF72.38
Buy
―
Reiterated
02/26/26
Guggenheim Sticks to Their Buy Rating for Celldex (CLDX)
Mizuho Securities Analyst forecast on CH:TCE1
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
CHF38.6
Buy
―
Reiterated
01/09/26
Celldex (CLDX) Gets a Buy from Mizuho Securities
Citi Analyst forecast on CH:TCE1
David Lebowitz
Citi
Citi
CHF45.03→CHF38.6
Buy
―
Reiterated
08/20/25
Celldex price target lowered to $48 from $56 at CitiCelldex price target lowered to $48 from $56 at Citi
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Celldex

3 Months
Derek ArchilaWells Fargo
Success Rate
8/11 ratings generated profit
73%
Average Return
+1.97%
Copying Derek Archila's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +1.97% per trade.
1 Year
Joseph PantginisH.C. Wainwright
Success Rate
13/14 ratings generated profit
93%
Average Return
+41.03%
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +41.03% per trade.
2 Years
Joseph PantginisH.C. Wainwright
Success Rate
14/14 ratings generated profit
100%
Average Return
+56.95%
Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +56.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TCE1 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
6
5
5
6
6
Buy
5
6
6
9
8
Hold
1
1
2
1
1
Sell
2
1
0
0
0
Strong Sell
0
0
0
0
0
total
14
13
13
16
15
In the current month, TCE1 has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TCE1 average Analyst price target in the past 3 months is 41.09.
Each month's total comprises the sum of three months' worth of ratings.

TCE1 Financial Forecast

TCE1 Earnings Forecast

Next quarter’s earnings estimate for TCE1 is -$0.85 with a range of -$0.94 to -$0.75. The previous quarter’s EPS was -$0.95. TCE1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year TCE1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for TCE1 is -$0.85 with a range of -$0.94 to -$0.75. The previous quarter’s EPS was -$0.95. TCE1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year TCE1 has Performed in-line its overall industry.

TCE1 Sales Forecast

Next quarter’s sales forecast for TCE1 is $594.92K with a range of $0.00 to $2.42M. The previous quarter’s sales results were $12.12K. TCE1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year TCE1 has Performed in-line its overall industry.
Next quarter’s sales forecast for TCE1 is $594.92K with a range of $0.00 to $2.42M. The previous quarter’s sales results were $12.12K. TCE1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year TCE1 has Performed in-line its overall industry.

TCE1 Stock Forecast FAQ

What is CH:TCE1’s average 12-month price target, according to analysts?
Based on analyst ratings, Celldex Therapeutics’s 12-month average price target is 41.09.
    What is CH:TCE1’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:TCE1, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Celldex Therapeutics a Buy, Sell or Hold?
        Celldex Therapeutics has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Celldex Therapeutics’s share price target?
          The average share price target for Celldex Therapeutics is 41.09. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $53.88 ,and the lowest forecast is $30.56. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Celldex Therapeutics?
            Celldex Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
              How can I buy shares of Celldex Therapeutics?
              To buy shares of CH:TCE1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.